Advances in pharmacological treatments of IBS.
Camilleri
Michael
M
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Charlton 8-110, 200 First Street SW, Rochester, MN 55905, USA. camillieri.michael@mayo.edu
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001593:Benzyl Compounds / Q000627:therapeutic use; D002243:Carbolines / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D009388:Neostigmine / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D011437:Propylamines / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D001593:Benzyl Compounds; D002243:Carbolines; D007211:Indoles; D011437:Propylamines; C090840:alosetron; D009388:Neostigmine; C105050:tegaserod; C067749:fedotozine; D003000:Clonidine